Global Ganja Report

To little fanfare, President Barack Obama on May 16 signed into law the Transnational Drug Trafficking Act—further extending the global reach of US narcotics enforcement. The law criminalizes manufacture of drugs anywhere in the world if the producers "intend, know, or have probable cause to believe" the substances will be illegally imported into the United States. The language has been attacked as overbroad, potentially applying to any link of the production chain—down to lowly peasant growers of cannabis, coca leaf or opium.

On Dec. 18, Congress approved a $1.1 trillion dollar spending bill—and in the process approved a provision promising to keep federal law enforcement out of medical marijuana operations in states that have passed acts legalizing them. The provision, known as the Rohrabacher-Farr amendment, was first approved in December of last year. The rider for a second year bars the use of Department of Justice funds "to prevent such States from implementing their own State laws that authorize the use, distribution, possession, or cultivation of medical marijuana."

Legislators on Capitol Hill passed three amendments June 3 to bar the DEA and Department of Justice from undermining state marijuana laws, as part of the US House of Representatives' consideration of the Fiscal Year 2016 Commerce, Justice, and Science Appropriations bill. "There’s unprecedented support on both sides of the aisle for ending the federal war on marijuana and letting states set their own drug policies based on science, compassion, health, and human rights," said Bill Piper, director of national affairs for the Drug Policy Alliance. "The more the DEA blocks sensible reforms the more they will see their agency's power and budget come under deeper scrutiny."

A bipartisan group of US Senators on March 10 announced legislation to end the federal ban on medical marijuana. The Compassionate Access, Research Expansion and Respect States (CARERS) Act is sponsored by senators Kirsten Gillibrand (D-NY) Rand Paul (R-KY) and Cory Booker (D-NJ). If passed, the bill would end the federal restriction on medical marijuana and allow for several comprehensive reforms, including: permission for limited interstate transport, an expansion of access to cannabis for research purposes, and reclassification of marijuana from Schedule I to II. Medical marijuana, and the right of states to determine how to regulate it, has found bipartisan support in both the House and Senate. (Jurist, March 10)

The House and Senate appropriations leadership has hammered out a budget bill that includes an historic amendment to curb federal Department of Justice (DoJ) enforcement in medical marijuana states. The measure, which was originally passed by the House in May with a 219-189 vote, aims to prohibit the DoJ from spending taxpayer money to undermine state medical marijuana laws. "This is great news for medical marijuana patients all across the country," said Rep. Sam Farr (D-CA), one of the co-authors of the House measure. "This amendment protects patients while the federal government catches up with the views of the American people. Patients will have access to the care legal in their state without fear of federal prosecution. And our federal dollars will be spent more wisely on fighting actual crimes and not wasted going after patients."

US representatives Earl Blumenauer (D-OR) and Dana Rohrabacher (R-CA), along with ten bipartisan co-sponsors introduced, the Veterans Equal Access Act (VEAA) Nov. 20, to allow our country's veterans to become medical marijuana patients in states where it's legal. The VEAA would allow Veterans Affairs (VA) physicians to recommend medical marijuana to their patients, a right enjoyed by physicians outside of the VA system. "Post traumatic stress and traumatic brain injury are just as damaging and harmful as any injuries that are visible from the outside," said Blumenauer, the bill's author. "Sometimes even more so because of the devastating effect they can have on a veteran's family. We should be allowing these wounded warriors access to the medicine that will help them survive and thrive, including medical marijuana, not treating them like criminals and forcing them into the shadows. It's shameful."

The US District Court for the Eastern District of California will hold rare formal hearings beginning Oct. 27 to determine whether an indictment against Brian Justin Pickard and others for conspiracy to grow more than 1,000 marijuana plants violates the US Constitution, and whether marijuana is misclassified by the federal government as a dangerous drug with no medical value. US District Judge Kimberly J. Mueller will preside over the three-day hearing, which includes expert testimony from doctors Carl Hart, associate professor of psychology at Columbia University in New York; Greg Carter, medical director of St. Luke's Rehabilitation Institute in Spokane, Wash., and expert witness Chris Conrad.

US Rep. Scott Perry (R-PA) on July 29 introduced a bill to legalize cannabidiol (CBD) oil on a national level, citing its effectiveness in treating seizures in children suffering from epilepsy. The "Charlotte's Web Medical Hemp Act of 2014" would remove CBD oil and "therapeutic hemp" from the federal definition of marijuana in the Controlled Substances Act. "Therapeutic hemp" is cannabis that contains no more than .3% THC and therefore produces no "high." Perry announced the bill at press conference where he was joined by the president of the national Epilepsy Foundation and advocates that included the mother of Colorado girl Charlotte Figi, whose successful treatment with  CBD  oil won national interest. Also present was Joel Stanley, one of the creators of the "Charlotte's Web" strain of marijuana used to treat Figi. Introduction of the legislation coincides with a pledge by Pennsylvania's Gov. Tom Corbett to create a state-level pilot program for families whose children require access to medical marijuana. (Jurist, July 29; PennLive, MSBC, July 28)